Wang H, Shan Q, Guo J, Han X, et al. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab. Lung Cancer 2021;151:76-83.
PMID: 33246647